On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsAudio – PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Unique Delivery Platform Could be a Breakthrough in Cannabinoid Drug Delivery

Company: PreveCeutical Medical Inc. (PRVCF)
Category: News

Related Editorial
Modern science has substantiated both the anecdotal history and the efficacy of cannabidiol (“CBD”), a non-psychoactive compound found in the cannabis sativa plant. Research has revealed that CBD may significantly reduce inflammation and is now widely used to treat chronic pain, multiple sclerosis and fibromyalgia, epilepsy, and numerous other conditions. There is even evidence that CBD has potential to prevent symptoms of Alzheimer’s and appears to suppress the growth of cancer cells and promote the death of these cells (http://nnw.fm/S6cXu). While CBD may provide solutions to multiple unmet medical needs, current drug delivery techniques remain antiquated. There are inherent metabolic issues in consistent, effective delivery of cannabinoids, and these new pharmaceutical therapeutics require revolutionary techniques of administration. Establishing a new paradigm in cannabinoid drug delivery, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (PRVCF Profile) is engineering a unique Sol-gel nose-to-brain delivery platform to provide direct, controlled pharmacological drug release. Many large Canadian companies produce cutting-edge pharmaceutical cannabis compounds, yet rely on outdated delivery mechanisms and may find PreveCeutical’s platform superior to current dosing techniques. Some of these companies include Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF), Aphria, Inc. (TSX: APH) (OTCQB: APHQF) and Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F).

To view the full editorial, visit http://nnw.fm/z62Bc

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217